These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32963537)

  • 1. Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.
    Owaidah TM; Alzahrani HA; Al-Numair NS; Alnosair AO; Aguilos AM; Saleh M
    Adv Hematol; 2020; 2020():8768074. PubMed ID: 32963537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrepancy between the results of one-stage and chromogenic factor VIII: C assays in patients with mild/moderate hemophilia A.
    Vosough F; Ahmadinejad M; Toogeh G; Karimi K; Homayoun S; Managhchi MR; Arabkhazaeli A
    Blood Coagul Fibrinolysis; 2020 Dec; 31(8):530-535. PubMed ID: 33141777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
    Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Chromogenic Factor VIII Assay Compared with One-Stage Clotting Assay.
    Akkaya E; Hatiboglu S; Koc B; Genc S; Unuvar A; Karaman S; Omer B; Karakas Z; Zulfikar B
    Clin Lab; 2020 Oct; 66(10):. PubMed ID: 33073956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?
    Schütte LM; Hodes LS; van Moort I; Stoof SCM; Leebeek FWG; Cnossen MH; de Maat MPM; Kruip MJHA
    Haemophilia; 2020 Sep; 26(5):916-922. PubMed ID: 32713129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and Hemostatic Potential in Persons with Mild to Moderate Hemophilia A with a Discrepancy between One-Stage and Chromogenic FVIII Assays.
    Strålfors A; Mikovic D; Schmidt D; Onelöv L; Soutari NMH; Berndtson M; Chaireti R; Holmström M; Antovic JP; Bruzelius M
    Thromb Haemost; 2021 Jan; 121(1):27-35. PubMed ID: 32791533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring standard and extended half-life products in hemophilia: Assay discrepancies for factor VIII and IX in pre- and postinfusion samples.
    Augustsson C; Norström E; Andersson NG; Zetterberg E; Astermark J; Strandberg K
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1114-1120. PubMed ID: 33134777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay discrepancy in mild haemophilia A.
    Armstrong E; Hillarp A
    Eur J Haematol Suppl; 2014 Aug; 76():48-50. PubMed ID: 24957107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-stage vs. chromogenic assays in haemophilia A.
    Potgieter JJ; Damgaard M; Hillarp A
    Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
    Zwagemaker AF; Kloosterman FR; Gouw SC; Boyce S; Brons P; Cnossen MH; Collins PW; Eikenboom J; Hay C; Hengeveld RCC; Jackson S; Klopper-Tol CAM; Kruip MJHA; Gorkom BL; Male C; Nieuwenhuizen L; Shapiro S; Fijnvandraat K; Coppens M;
    J Thromb Haemost; 2023 Apr; 21(4):850-861. PubMed ID: 36696222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
    Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
    Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays.
    Duncan EM; Rodgers SE; McRae SJ
    Semin Thromb Hemost; 2013 Apr; 39(3):272-82. PubMed ID: 23460037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays.
    Valikhani A; Mirakhorly M; Namvar A; Rastegarlari G; Toogeh G; Shirayeh FV; Ahmadinejad M
    Transfus Apher Sci; 2021 Oct; 60(5):103194. PubMed ID: 34275734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
    Augustsson C; Norström E; Lind V; Martin M; Astermark J; Strandberg K
    Haemophilia; 2021 May; 27(3):494-500. PubMed ID: 33866649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.
    Rodgers SE; Duncan EM; Barbulescu DM; Quinn DM; Lloyd JV
    Br J Haematol; 2007 Jan; 136(1):138-45. PubMed ID: 17222201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.